Sign in
Taking people in United StatesPhase 1

Stem cells from umbilical cord or placenta infused into a vein for cerebral palsy

Tests the safety of stem cell infusions in people with cerebral palsy.

Key facts

Who runs it
The Foundation for Orthopaedics and Regenerative Medicine
Where
Naples, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP
Status
Recruiting
Phase
Phase 1
People taking part
15 people, planned
Starts
Dec 2026
Expected to end
Dec 2028
Type of study
Interventional
Treatments tested
  • Umbilical or placental derived mesenchymal stem cells
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with cerebral palsy. They get one drip into a vein of stem cells taken from umbilical cord or placenta.

Sex
All sexes can join.
Disease stage
A diagnosis of cerebral palsy.
Earlier treatment
People who have had an organ transplant before cannot join.

Main reasons for not taking part

  • Active infection or active cancer
  • Long-term failure of several organs
  • Pregnancy
  • Seizure disorder (epilepsy)
  • Allergy to sulfur, or clearly abnormal blood tests before treatment

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Diagnosis of Cerebral Palsy

Who cannot take part

  • Previous organ transplant
  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety
  • Seizure disorder
  • Hypersensitivity to sulfur
  • Clinically significant Abnormalities on pre-treatment laboratory evaluation
  • Pregnancy

Where in United States

Also in 1 other country, 1 site

  • Prodromos Stem Cell InstituteNaples, United StatesContact: Chadwick Prodromos, MDTaking people

About the trial

What the trial wants to find out

This trial will study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of Cerebral Palsy

The group in the trial

  • Treatment GroupTreatment being tested

    Single intravenous infusion of 100 million cells

    Treatment: Umbilical or placental derived mesenchymal stem cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy
Plain-language title
Stem cells from umbilical cord or placenta infused into a vein for cerebral palsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
16 October 2026
Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP (NCT05018871) – Frontlight Research